Aptose Biosciences Inc (APS : TSX)
Common Stock
Follow APS
APS
Aptose Biosciences Inc
Performance
1 Day
+0.00%
1 Week
+0.00%
1 Month
+0.00%
YTD
+18.81%
The Tuesday Stock Pick · free, every tuesday morning. One Canadian stock and the case for it.
Key Statistics
Market Cap
$6.13M
52W High
$2.59
52W Low
$1.41
P/E Ratio
-
50 Day MA
$2.25
200 Day MA
$2.14
Beta
0.34
Dividend Yield
-
Performance history
APS returns since 2023
Aptose Biosciences Inc has traded since Nov 2023 in our data, with 1 up year out of 2 full calendar years. Its deepest fall was −95.1% (Nov 2023 to Feb 2025).
1 year / yr
+101.7%
3 years / yr
—
5 years / yr
—
10 years / yr
—
Calendar-year returns
- 2023*−21.5%
- 2024−90.1%
- 2025+542.4%
- 2026*+13.2%
* Partial year (first year of data, or year to date).
$10,000 invested in APS
- 1 year ago$20,168
- 2023 (start of our data)$5,621
- Best year
- 2025: +542.4%
- Worst year
- 2024: −90.1%
- All-time high in our data
- $6 on Mar 20, 2025 · now −57.6%
Total-return basis using adjusted daily closes from the Toronto Stock Exchange and TSX Venture (dividends and splits folded in), Nov 2023 to Jul 2026. Past returns do not predict future ones.
Awesome Portfolio™
Looking past APS? Our 10 best Canadian stocks, in one list.
14.8% a year since 2017 against 9.7% for the S&P/TSX Composite (+5.0 points a year). Reviewed every month.
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 7/3/2026 | $2.40 | $2.40 | $2.40 | $2.40 | $2.40 | 2,945 |
| 7/2/2026 | $2.40 | $2.41 | $2.40 | $2.40 | $2.40 | 32,232 |
| 6/30/2026 | $2.13 | $2.14 | $2.13 | $2.14 | $2.14 | 200 |
| 6/29/2026 | $2.25 | $2.25 | $2.25 | $2.25 | $2.25 | 0 |
| 6/26/2026 | $2.20 | $2.25 | $2.20 | $2.25 | $2.25 | 305 |
| 6/25/2026 | $2.20 | $2.20 | $2.20 | $2.20 | $2.20 | 100 |
| 6/24/2026 | $2.20 | $2.20 | $2.20 | $2.20 | $2.20 | 3,010 |
| 6/23/2026 | $2.12 | $2.13 | $2.12 | $2.13 | $2.13 | 1,100 |
| 6/22/2026 | $2.08 | $2.20 | $2.08 | $2.12 | $2.12 | 1,196 |
| 6/19/2026 | $2.20 | $2.20 | $2.20 | $2.20 | $2.20 | 0 |
Analyst Price Targets
Based on analyst covering APS · as of Sep 17, 2026
Wall Street analysts forecast APS stock price to fall 1.7% over the next 12 months.
Consensus
NeutralBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$2.36
-1.7% Upside
Current Price
C$2.40
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on APS's historical volatility
30-Day Vol
52.7%
Annualized
90-Day Vol
48.9%
Annualized
Trend (90d)
-0.0%
Annualized drift
90d Mean
C$2.40
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$2.40 | C$2.00 – C$2.88 |
| 60 trading days | C$2.40 | C$1.86 – C$3.10 |
| 90 trading days | C$2.40 | C$1.75 – C$3.29 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Aptose Biosciences Inc
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops precision medicines addressing unmet medical needs in oncology primarily in the United States. The company's clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes. It has license agreements with National Cancer Institute for the clinical development of tuspetinib; and Hanmi Pharmaceutical Co Ltd. to research, develop, and commercialize tuspetinib. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.
Financials
- Revenue (TTM)
- $0
- EBITDA
- $-26.42M
- Profit Margin
- 0.00%
- ROE (TTM)
- -694.13%
- EPS (Diluted)
- -14.78
- Book Value
- -19.30
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
Free newsletter
The Tuesday Stock Pick
One Canadian stock and the case for it
- The name with the biggest gap to analyst targets
- The chart, insider buying and what is driving it
- A plain-English bottom line, no hype
Explore More
Common Questions About APS
Market movers
Recent TSX movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| HWO | High Arctic Energy Services Inc. | $1.74 | +29.85% |
| AAV | Advantage Oil & Gas Ltd. | $13.45 | +23.74% |
| LUC | Lucara Diamond Corp | $0.13 | +13.64% |
| T | Telus Corp | $13.70 | +12.85% |
| FRX | Fennec Pharmaceuticals Inc | $18.35 | +10.81% |
| KEL | Kelt Exploration Ltd. | $12.72 | +10.70% |
| NVO | Novo Resources Corp | $0.07 | +8.33% |
| ELO | Eloro Resources Ltd. | $1.23 | +7.89% |
Free with a Wealth Awesome account
Keep analysing APS, free
- Every WA Score, ranking and table
- Insider track records and SEDI filings
- Earnings history and analyst targets for every stock
Email only, no password, no card. Already a member? Use the same button to sign in.
